Skip to main content
Irwin Naturals Inc. logo

Irwin Naturals Inc. — Investor Relations & Filings

Ticker · IWIN ISIN · CA46414Q1054 LEI · 9845003CF0B7JE8FAX54 CSE Manufacturing
Open in API
Filings indexed 255 across all filing types
Latest filing 2022-12-03 Regulatory Filings
Country CA Canada
Listing CSE IWIN

About Irwin Naturals Inc.

https://irwinnaturals.com/

Irwin Naturals Inc. is a nutraceutical company focused on developing and distributing premium health supplements and vitamins. The company specializes in soft-gel based herbal formulas, prioritizing superior potency, bioavailability, and absorption. Its product portfolio includes targeted formulas for general wellness, sleep, cognitive function, detoxification, and weight management, alongside a range of CBD and THC products. A core unique selling proposition is the utilization of an all-liquid soft-gel delivery system combined with the signature BioPerine Complex, which is designed to enhance nutrient uptake. Irwin Naturals distributes its extensive line of supplements through mass-market and health food chain retailers across North America.

Recent filings

Filing Released Lang Actions
Interim financial statements/report (amended) - English.pdf
Regulatory Filings
2022-12-03 English
News release - English.pdf
Regulatory Filings
2022-12-02 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Combined Consolidated Interim Financial Statements' and covers financial data for the three and nine months ended September 30, 2022 and 2021. It includes unaudited interim financial statements such as the statement of financial position, profit and comprehensive income, changes in equity, cash flows, and notes. The document explicitly states it is an interim report and contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-12-02 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CFO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2022. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references the interim filings but does not include them. According to the CERTIFICATION RULE, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (2998 characters), consistent with a certification letter rather than a full report.
2022-11-30 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CEO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2022. The document is primarily an officer certification letter and does not contain actual financial data or the interim report itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is 3001 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2022-11-30 English
Interim MD&A - English.pdf
Regulatory Filings
2022-11-30 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.